Loading viewer...
investor_presentation
Format: PDF investor_presentation
First Quarter 2020 Earnings April 24, 2020
First Quarter 2020 Earnings April 24, 2020IDEX Proprietary & ConfidentialAgenda
IDEX Performance Drivers
•Break Even Analysis
2IDEX Proprietary & ConfidentialReplay Information
•Dial toll –free: 877.660.6853
•International: 201.612.7415
•Conference ID: #13694804
•Log on to: www.idexcorp.com
3IDEX Proprietary & ConfidentialCautionary Statement
Cautionary Statement Under the Private Securities Litigation Reform Act; Non -GAAP Measures
The Securities and Exchange Commission encourages companies to disclose forward -looking information so that investors can better understand the
future prospects of a company and make informed investment decisions. This presentation and discussion may contain “forward -looking” statements within
the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the anticipated
effects of the coronavirus pandemic, including with respect to the Company's sales, facility closures, supply chains and acce ss to capital, capital
expenditures, acquisitions, cost reductions, cash flow, revenues, earnings, market conditions, global economies and operating improvements, and are
indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “expects,” “projects,” “forecasts,” “should,” “cou ld,” “will,” “management believes,”
“the Company believes,” “the Company intends,” and similar words or phrases. These statements are subject to inherent uncerta inties and risks that could
cause actual results to differ materially from those anticipated at the date of this news release. The risks and uncertaintie s include, but are not limited to, the
following: the duration of the coronavirus pandemic and the effects of the coronavirus on our ability to operate our business and facilities, on our customers,
on supply chains and on the U.S. and global economy generally; economic and political consequences resulting from terrorist a ttacks and wars; levels of
industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other com petitive factors and levels of
capital spending in certain industries, all of which could have a material impact on order rates and the Company's results, p articularly in light of the low
levels of order backlogs it typically maintains; the Company's ability to make acquisitions and to integrate and operate acqu ired businesses on a profitable
basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political andeconomic conditions in foreign
countries in which the Company operates; developments with respect to trade policy and tariffs; interest rates; capacity util ization and the effect this has on
costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigatio n and environmental matters.
Preview truncated — download the full document for the complete content.
investor_presentation
15 Pages
investor_presentation
19 Pages
Halozyme Therapeutics